BSE Pharma Sector Regulatory Filings — July 27, 2026

27-07-2026

Alkem Laboratories Ltd. has informed the stock exchanges that it will hold a conference call for investors and analysts on August 14, 2026, at 4:30 pm IST to discuss its Q1FY27 financial results. The call will be hosted by Motilal Oswal Securities Ltd. and will feature the Managing Director and CFO. No financial results or performance data are disclosed in this filing.

• · Conference call date: Friday, August 14, 2026
• · Call time: 4:30 pm to 5:30 pm IST
• · Dial-in numbers provided for India, USA, UK, Singapore, and Hong Kong
• · Express join available via Diamond Pass registration link
• · Participants are requested to dial in 10 minutes before the scheduled start

27-07-2026

Sun Pharmaceutical Industries Limited has informed the exchanges that its partner Philogen has resubmitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Nidlegy™ (Daromun), an investigational neoadjuvant treatment for locally advanced, fully resectable melanoma. The updated application is based on longer follow-up data (33 months vs. 21 months) from the Phase III PIVOTAL study, which showed Nidlegy reduced the risk of relapse or death, and includes additional CMC information to address prior regulatory questions. While the resubmission represents progress, the drug remains investigational and regulatory approval is not guaranteed.

• · The updated MAA includes additional post-hoc analyses focused on event-free survival.
• · Clinical data from the 2024 submission were published in Annals of Oncology (Kähler et al., 2025, 36, 1166).
• · Updated data have been accepted for publication in the Journal of Clinical Oncology (doi 10.1200/JCO-26-00852).
• · Safety profile of Nidlegy was characterized mostly by low-grade, local adverse events.
• · Additional supporting data include safety data from the ongoing Phase III NeoDREAM study and Phase II studies in non-melanoma skin cancer.
• · Nidlegy is partnered with Sun Pharma for Europe, New Zealand, and Australia.
• · There is currently no approved drug for neoadjuvant treatment of locally advanced fully resectable melanoma.

27-07-2026

Pfizer Limited announced the resignation of Mr. Amit Agarwal as Executive Director – Finance & Chief Financial Officer, effective October 8, 2026, to pursue an opportunity outside the company. He will also cease to be a Director and member of certain board committees. The resignation is effective after a notice period of over two months.

• · Mr. Agarwal's resignation is effective from close of business on October 8, 2026.
• · He will cease to be a Director and member of the CSR Committee, Risk Management Committee, and Board Administrative & Share Transfer Committee.
• · The resignation is to pursue an opportunity outside Pfizer Limited.
• · The company disclosed the information under Regulation 30 of SEBI LODR Regulations.

27-07-2026

Cipla reported Q1 FY27 revenue of INR7,119 crore (2% YoY growth, or ~4% adjusted for accounting change), with One India business achieving its highest-ever quarterly revenue at 12% YoY growth. However, EBITDA margin was 16.7%, gross margin 62.5% (impacted by product mix and one-time costs), and PAT stood at INR789 crore (11% of sales). North America revenue was $162 million, while South Africa private market grew 6.5% but overall SA revenue declined ~5% in rupee terms. The company highlighted a strong chronic mix (60.4%) and new product launches, but also noted a Form 483 at Invagen and an upcoming Indore reinspection.

• · Accounting change effective April 1, 2026: certain marketing and proportional expenditures now shown as reduction from revenue instead of operating expenditure.
• · Adjusted YoY revenue growth is ~4% (vs reported 2%) after accounting change.
• · South Africa revenue decline of ~5% in rupee terms is largely due to the accounting adjustment.
• · Yurpeak contributed approximately INR80 crore to India revenue (about 1.5% of Rx growth).
• · Cipla holds 21% market share in US Albuterol MDI market.
• · US FDA classified Verna, Goa facility inspection as VAI; Invagen facility received one Form 483 observation; Indore reinspection expected soon.
• · Free cash flow generation and operating efficiency driving healthy net cash position of INR9,494 crore after dividend payment of INR1,050 crore.
• · New Global CFO Dinesh Jain (30+ years at Cipla) has taken over from Ashish Adukia.
• · Planned US pipeline includes 4 significant launches: 3 respiratory assets (including generic Advair) and a key peptide opportunity.
• · Two of the three respiratory assets filed from US manufacturing facilities; third from Goa facility.

27-07-2026

Aurobindo Pharma Limited has informed the stock exchanges that a Board Meeting will be held on August 5, 2026, to consider and approve the standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026. The trading window remains closed from July 1, 2026, until August 7, 2026, and will reopen on August 8, 2026.

• · Board meeting scheduled for August 5, 2026.
• · Trading window closure period: July 1, 2026 to August 7, 2026.
• · Trading window reopens on August 8, 2026.

27-07-2026

Mankind Pharma Limited has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of ₹49 Crore, subject to closing adjustments. The transaction was executed via a Share Purchase Agreement on July 27, 2026, following an earlier intimation on July 11, 2026. This is a final update on the stake sale, with no financial performance metrics to compare.

• · The Share Purchase Agreement was executed on July 27, 2026.
• · The sale is for 100% stake in Broadway Hospitality Services Private Limited.
• · Consideration is subject to closing adjustments.
• · Detailed disclosure under Regulation 30 was submitted on July 11, 2026.

27-07-2026

Torrent Pharmaceuticals has received final listing and trading approval from NSE and BSE for 4,19,22,416 equity shares issued to shareholders of JB Chemicals & Pharmaceuticals Limited under the Scheme of Amalgamation. The shares will be listed and admitted for trading effective July 28, 2026, marking a key milestone in the merger completion process.

• · Record date for share entitlement was July 17, 2026
• · Shares were allotted on July 20, 2026
• · Final listing approval received from both NSE and BSE on July 27, 2026
• · Trading commences from July 28, 2026